Senate Health, Education, Labor and Pensions Committee voted 15-5 to approve a expenses that aims to reinforce FDA oversight of medication organization advertising and post-authorization follow-up studies. The expenses was sponsored by Wyoming Republican Sen. Mike Enzi and Massachusetts Democrat Sen. Edward Kennedy. The principal motive for the expenses is to provide the FDA more power to stop another Vioxx disaster from being repeated. The Bush Administration can be against the bill and offered sharp objections to the bill’s provisions, saying it would decelerate drug approvals.Early access customers may begin with a summary of genes where they are interested, and Cellular Analysis shall generate the precise panel of assays for them. Related StoriesUT Southwestern's Helen H. Hobbs called recipient of Breakthrough Prize in Life SciencesClaritas Genomics announces launch of Claritas Clinical Exome, novel diagnostic testAutism Speaks launches web-structured portal for MSSNG databaseSeveral high profile research and commercial clients possess validated the assays and extra interested users should get in touch with Cellular Analysis.